Avation Medical appoints Darren Wennen, a medical industry veteran, as
Chief Marketing Officer in anticipation of commercialization of its
wearable neuromodulation system to treat OAB and UUI.
COLUMBUS, Ohio, April 13,
2022 /PRNewswire/ -- Avation Medical, an
innovative neuromodulation and digital health company pioneering a
wearable system to treat the symptoms of overactive bladder (OAB)
and urge urinary incontinence (UUI), today announced the
appointment of Darren Wennen as its
Chief Marketing Officer. He will be responsible for all
aspects of marketing, sales operations and customer care as the
Company prepares to bring its novel wearable therapy and digital
support system to market.
Avation Medical appoints CMO in
anticipation of launch of wearable neuromodulation system to treat
OAB & UUI
"I am thrilled to welcome Darren to Avation Medical. His
commercial experience and track record of growth is the ideal
addition to our team as we prepare to launch our category-changing
technology for patients suffering from OAB and UUI," said Jill
Schiaparelli, Avation's CEO. "Darren joins a strong team of
professionals at Avation that is committed to making
neuromodulation more accessible to patients suffering from chronic
conditions through its wearable therapy and digitally enabled
behavioral support platform."
"I am very excited about the potential for Avation's easy-to-use
wearable therapy system," added Mr. Wennen. "The 42 million
Americans with OAB and UUI have sent a clear message that they want
an effective treatment option that does not require surgery,
permanent implants or the side-effects of medication. Our system
combines non-invasive neuromodulation therapy with a digitally
enabled behavioral support system, offering patients a new option
that is effective, convenient, and safe."
Mr. Wennen brings to Avation Medical a demonstrated history of
successful product launches and sales growth. Most recently, Mr.
Wennen served as VP of Marketing and Clinical Affairs, as well as
SVP of Commercial Operations, for Tactile Medical (NASDAQ: TCMD),
where he helped to develop an underserved, reimbursement driven DME
wearable market in lymphedema, to grow the company to over
$200 million in sales and to complete
an IPO on NASDAQ. Earlier in his career, Mr. Wennen held leadership
roles with Stryker Orthopedics, Gyrus/ACMI (now Olympus), St. Jude
Medical (now Abbott) and Sterilmed (a J&J Company). Mr.
Wennen holds an MBA in marketing and international finance from the
University of St. Thomas (St. Paul,
MN), and a bachelor's degree from the University of Minnesota.
About Avation Medical
Avation Medical is an innovative neuromodulation and digital
health company with a mission to make neuromodulation more
accessible to patients across a variety of clinical conditions by
eliminating the need for surgery, permanent implants and the
side-effects of medications and shifting treatment to the home
environment. The Company's novel platform combines
non-invasive neuromodulation therapy with digital health tools to
offer a complete therapy and support system across a range of
chronic conditions. The Company's intelligent wearable
therapy objectively confirms activation of the target nerve, sets a
personalized therapeutic range for each patient, and delivers
clinically effective therapy in just 30 minutes. The
Company's first product, a wearable neuromodulation and digitally
enabled behavior support system for OAB and UUI, is currently
available for investigational use only and is not FDA cleared.
Corporate Contact:
Jackie Gerberry
Senior Director
Jackie@Avation.com
www.Avation.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/avation-medical-announces-appointment-of-chief-marketing-officer-to-executive-leadership-team-301524971.html
SOURCE Avation Medical